Enteric Coated Mycophenolate Sodium is Therapeutically Equivalent to Mycophenolate Mofetil in de novoRenal Transplant Patients
Top Cited Papers
Open Access
- 1 February 2004
- journal article
- clinical trial
- Published by Elsevier in American Journal of Transplantation
- Vol. 4 (2), 231-236
- https://doi.org/10.1046/j.1600-6143.2003.00337.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration1Transplantation, 2003
- Adverse Gastrointestinal Effects of Mycophenolate MofetilDrug Safety, 2001
- MYCOPHENOLATE MOFETIL REDUCES LATE RENAL ALLOGRAFT LOSS INDEPENDENT OF ACUTE REJECTIONTransplantation, 2000
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- Current thinking on chronic renal allograft rejection: Issues, concerns, and recommendations from a 1997 roundtable discussionAmerican Journal of Kidney Diseases, 1999
- A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1Transplantation, 1996
- Mechanism of Action of Mycophenolate MofetilTherapeutic Drug Monitoring, 1995
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995
- Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejectionThe Lancet, 1995